Skip to main content

Diana Fernandes de Rafael

I possess a Master in Pharmaceutical Sciences (2010) granted by the Faculty of Pharmacy from the Lisbon University, and a PhD degree in Pharmaceutical Technology (2017) from the same University. During my PhD I had the opportunity to do research stays at Ludwig Maximillian University (LMU), Munich, Bellvitge Biomedical Research Institute (IDIBELL) and Vall D'Hebron Research Institute (VHIR), Barcelona. Actually, I am a post-doctoral researcher at Drug Delivery and Targeting Group, VHIR working in the field of nanotechnology-based drug delivery systems applied to several diseases.

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Diana Fernandes de Rafael

Diana Fernandes de Rafael

Diana Fernandes de Rafael

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

I possess a Master in Pharmaceutical Sciences (2010) granted by the Faculty of Pharmacy from the Lisbon University, and a PhD degree in Pharmaceutical Technology (2017) from the same University. During my PhD I had the opportunity to do research stays at Ludwig Maximillian University (LMU), Munich, Bellvitge Biomedical Research Institute (IDIBELL) and Vall D'Hebron Research Institute (VHIR), Barcelona. Actually, I am a post-doctoral researcher at Drug Delivery and Targeting Group, VHIR working in the field of nanotechnology-based drug delivery systems applied to several diseases.

Being a multidisciplinary scientist, during 10 years of research career I acquired expertise in different areas of knowledge such as Pharmaceutical Technology, Nanomedicine, Chemistry, Molecular Biology, Cancer Signalling Pathways, Preclinical Validation, etc. My board knowledge in the field of biomedical sciences granted by my training as pharmacist and my research experience, allowed me to have a comprehensive and integrative view of the different stages of drug development from the bench to the bedside. My career has been fully dedicated to the design, development, and preclinical validation of innovative delivery systems for a wide range of challenging diseases with a special attention to oncology.
My active participation at different international projects (12) and collaborations with a variety of research groups have resulted in the authorship of several publications in high impact peer-reviewed journals (35 publications, 15 as corresponding/first author, h-index 18). Also, she is co-inventor of two patents about delivery systems for gene delivery and the creation of cell penetrating peptides. Moreover, I am truly active in science dissemination both to share the knowhow with the pairs at international conferences, and also in citizenship dissemination actions. Additionally, due to her experience in the fields of Pharmaceutical Technology and Molecular Biology, I am giving classes at the Master of Molecular Biotechnology from the University of Barcelona. Most importantly, I was responsible for the supervision of the thesis of different pre-graduated, master and PhD students (14).

Projects

NanoDIRE-CT - Uso de nanobodies para terapia dirigida contra células madre tumorales

IP: -
Collaborators: Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 322172.61
Reference: RTC2019-006809-1
Duration: 01/09/2020 - 31/12/2023

Ministerio de Ciencia

BIODEGRADABLE NANOPARTICLES OF SIMVASTATIN AS NEW THERAPEUTIC TOOL FOR CHRONIC LIVER DISEASE (NANOSIM)

IP: Joan Genescà Ferrer
Collaborators: Maria Nieves Martell Pérez-Alcalde, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 199946.45
Reference: AC18/00033
Duration: 01/01/2019 - 31/12/2022

Desenvolupament de noves nanopartícules funcionals dirigides al nòdul limfàtic per a l'eliminació del reservori latent de VIH

IP: María José Buzón Gómez
Collaborators: Félix Pumarola Segura, Juan Lorente Guerrero, Laura García Latorre, Jordi Temprana Salvador, Joaquin Seras Franzoso, Marc Pellicer Sarasa, Simon Schwartz Navarro, Jordi Navarro Mercadé, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Judit Grau Exposito, Meritxell Genesca Ferrer, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael
Funding agency: Fundació La Marató de TV3
Funding: 199998.75
Reference: 20180510
Duration: 10/05/2019 - 31/12/2022

Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados.

IP: -
Collaborators: Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 116160
Reference: PI18/00871
Duration: 01/01/2019 - 30/06/2022

Related news

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

Related professionals

Lluís Viladomiu Catà

Lluís Viladomiu Catà

Liver Diseases
Read more
María Antolín Mate

María Antolín Mate

Physiology and Pathophysiology of the Digestive Tract
Read more
Julieta Torchia

Julieta Torchia

Predoctoral researcher
Kidney Physiopathology
Read more
Aina Llenas Bladé

Aina Llenas Bladé

Research technician
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.